You are here: Industry Insights > Alzheimer’s

News List

FiercePharmaAsia—Biogen-Eisai Alzheimer’s data, China vaccine scandal, BMS-Tsinghua deal fiercepharma
July 30, 2018
To investors, Eisai and partner Biogen's recent phase 3 Alzheimer's data on anti-amyloid candidate BAN2401 aren't good enough.....
Can aspirin treat Alzheimer’s? biospectrumasia
July 04, 2018
A study shows low-dose aspirin may aid removal of harmful amyloid plaque in the brain…
Diabetes drugs show promise to treat symptoms of Alzheimer’s europeanpharmaceuticalreview
May 22, 2018
Discovery of a pathway linking Alzheimer’s disease and Type 2 diabetes leads to new strategies to preserve brain health…
Opioid analgesics reduce the use of antipsychotics in Alzheimer’s disease europeanpharmaceuticalreview
March 30, 2018
Initiating an opioid analgesic reduced the use of antipsychotics and benzodiazepines in persons with Alzheimer’s disease…
27 Phase III and 8 Phase II Alzheimer’s drugs on track to launch in next 5 years europeanpharmaceuticalreview
July 20, 2017
Twenty-seven Alzheimer’s drugs in Phase III clinical trials and eight drugs in Phase II clinical trials may launch in the next five years…
New Study Presented at Alzheimer’s Association International Conference 2017 (AAIC) Validates Equiva b3cnewswire
July 18, 2017
Widespread availability of self-administered eSAGE (BrainTest® https://braintest.com) expected to be a major factor in overcoming the many obstacles in identifying early cognitive impairment
Plant based medicine to treat Alzheimer’s biospectrumasia
June 23, 2017
During their research, they found that three compounds from the plant- naringenin and two of its metabolites had made it into the brain.
WNIF: Combating Alzheimer’s Together lilly
March 23, 2017
This article comes from Phyllis Ferrell, Lilly’s vice president and platform development leader for the global Alzheimer’s disease team.
MSD’s Alzheimer’s drug failure undermines potential treatment pathway pharmafile
February 16, 2017
MSD has announced that it has been forced to cancel a Phase 2/3 trial studying the potential therapeutic effects of verubecestat in Alzheimer’s patients.

Previous page 1 2 3 Next page